Advaxis, Inc. “A Win-Win in Pet Therapeutics”

Philadelphia, PA / March 21, 2014 / Advaxis,

Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman’s

Blog, written by the Company’s EVP and COO, Mr. Gregory T. Mayes.

TheChairmansBlog.com is an exclusive online media publication that

enables key executive officers a unique platform to share insights

about their company and industry trends.

Mr.

Mayes discusses the Company’s recently announced agreement with

Aratana, which will be focused on cancer immunotherapies for pets.

His new blog outlines the “win win” situation he believes the

collaboration presents, writing, “…the biggest winners of all are

the patients -- both humans and dogs.” Read the full blog post

from Mr. Gregory T. Mayes on TheChairmansBlog.com

(www.thechairmansblog.com/advaxis/gregory-mayes/win-in-pet-therapeutics)





About

Advaxis, Inc.

Advaxis

is a clinical-stage biotechnology company developing the next

generation of cancer immunotherapies. Advaxis's immunotherapies are

based on a novel platform technology using live, attenuated bacteria

to stimulate the immune system to selectively target cancer cells

while reducing tumor defenses.



ADXS-HPV,

Advaxis's lead immunotherapy for the treatment of HPV-associated

cancers, has demonstrated improved survival and objective tumor

responses in a Phase 2 trial in 110 patients with recurrent cervical

cancer. Advaxis is now planning the registrational program for

ADXS-HPV. ADXS-HPV is also being evaluated in other HPV-associated

cancers including a Phase 2 in advanced cervical cancer, a Phase 1/2

in head and neck cancer, and a Phase 1/2 in anal cancer. ADXS-HPV has

orphan drug status for both anal and head and neck cancers. As part

of its global commercialization strategy to enter into regional

licensing deals with other market dominant biopharmaceutical

companies in territories where there is a high prevalence of

HPV-associated cancers, Advaxis has granted exclusive licenses for

the development and commercialization of ADXS-HPV in Asia and India.



ADXS-cHER2

is an immunotherapy for the treatment of HER2 overexpressing cancers

(such as breast, gastric, esophageal, and other cancers in humans and

for osteosarcoma in canines). Advaxis's lead animal-health

immunotherapy, ADXS-cHER2, has demonstrated encouraging survival data

in a Phase 1 trial in canine osteosarcoma. These data provide the

rationale to advance this same immunotherapy into a Phase 1 clinical

trial in women with HER2-positive breast cancer. The Company is

preparing an IND submission for ADXS-cHER2 in breast cancer in 2014.



Advaxis

has created more than 20 distinct immunotherapies based on its

platform, either directly or through strategic collaborations with

recognized cancer centers of excellence. We have clinical research

collaborations with the University of Pennsylvania, Brown University,

the Georgia Regents University Cancer Center, the Icahn School of

Medicine at Mount Sinai, and others.



For

more information, visit http://www.advaxis.com/.



About

TheChairmansBlog.com



TheChairmansBlog.com

is an exclusive, online media publication where publicly and

privatively held firms alike share insights about their companies and

industries. TheChairmansBlog.com enables upper tier management to

discuss issues that are of importance to their stakeholders,

shareholders, and interested parties in an informal environment.

www.thechairmansblog.com

Release ID: 37317